Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label metreleptin study in partial lipodystrophy
2022-502950-14-00Phase 4Authorised
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of metreleptin in partial lipodystrophy, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: HbA1c responder rate at Month 12 and Triglyceride responder rate at Month 12. Planned start Dec 2023; status: authorised.
02
Drugs
metreleptin
03
Conditions
partial lipodystrophy
Beyond the preview
Go deeper on 2022-502950-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502950-14-00.